These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

268 related items for PubMed ID: 31764978

  • 21. Assessing proarrhythmic potential of environmental chemicals using a high throughput in vitro-in silico model with human induced pluripotent stem cell-derived cardiomyocytes.
    Lin HC, Rusyn I, Chiu WA.
    ALTEX; 2024 Jan 09; 41(1):37-49. PubMed ID: 37921411
    [Abstract] [Full Text] [Related]

  • 22. CSAHi study: Validation of multi-electrode array systems (MEA60/2100) for prediction of drug-induced proarrhythmia using human iPS cell-derived cardiomyocytes -assessment of inter-facility and cells lot-to-lot-variability.
    Nozaki Y, Honda Y, Watanabe H, Saiki S, Koyabu K, Itoh T, Nagasawa C, Nakamori C, Nakayama C, Iwasaki H, Suzuki S, Washio I, Takahashi E, Miyamoto K, Yamanishi A, Endo H, Shinozaki J, Nogawa H, Kunimatsu T.
    Regul Toxicol Pharmacol; 2016 Jun 09; 77():75-86. PubMed ID: 26884090
    [Abstract] [Full Text] [Related]

  • 23.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 24. Cardiotoxicity screening with simultaneous optogenetic pacing, voltage imaging and calcium imaging.
    Dempsey GT, Chaudhary KW, Atwater N, Nguyen C, Brown BS, McNeish JD, Cohen AE, Kralj JM.
    J Pharmacol Toxicol Methods; 2016 Jun 09; 81():240-50. PubMed ID: 27184445
    [Abstract] [Full Text] [Related]

  • 25. Effects of Serum and Compound Preparation Methods on Delayed Repolarization Evaluation With Human iPSC-CMs.
    Wei F, Pence L, Woodling K, Bagam P, Beger R, Gamboa da Costa G, Pang L.
    Toxicol Sci; 2022 Jun 28; 188(1):48-61. PubMed ID: 35478258
    [Abstract] [Full Text] [Related]

  • 26.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 27.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 28.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 29. Cross - site comparison of excitation-contraction coupling using impedance and field potential recordings in hiPSC cardiomyocytes.
    Bot CT, Juhasz K, Haeusermann F, Polonchuk L, Traebert M, Stoelzle-Feix S.
    J Pharmacol Toxicol Methods; 2018 Jun 28; 93():46-58. PubMed ID: 29940218
    [Abstract] [Full Text] [Related]

  • 30. Comparative pharmacology of guinea pig cardiac myocyte and cloned hERG (I(Kr)) channel.
    Davie C, Pierre-Valentin J, Pollard C, Standen N, Mitcheson J, Alexander P, Thong B.
    J Cardiovasc Electrophysiol; 2004 Nov 28; 15(11):1302-9. PubMed ID: 15574182
    [Abstract] [Full Text] [Related]

  • 31. The Use of iPSC-Derived Cardiomyocytes and Optical Mapping for Erythromycin Arrhythmogenicity Testing.
    Podgurskaya AD, Tsvelaya VA, Slotvitsky MM, Dementyeva EV, Valetdinova KR, Agladze KI.
    Cardiovasc Toxicol; 2019 Dec 28; 19(6):518-528. PubMed ID: 31165980
    [Abstract] [Full Text] [Related]

  • 32. Assessment of drug-induced proarrhythmia: The importance of study design in the rabbit left ventricular wedge model.
    Lu HR, Gallacher DJ, Yan GX.
    J Pharmacol Toxicol Methods; 2016 Dec 28; 81():151-60. PubMed ID: 27374776
    [Abstract] [Full Text] [Related]

  • 33.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 34.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 35. Electrophysiological Characteristics of Human iPSC-Derived Cardiomyocytes for the Assessment of Drug-Induced Proarrhythmic Potential.
    Yamamoto W, Asakura K, Ando H, Taniguchi T, Ojima A, Uda T, Osada T, Hayashi S, Kasai C, Miyamoto N, Tashibu H, Yoshinaga T, Yamazaki D, Sugiyama A, Kanda Y, Sawada K, Sekino Y.
    PLoS One; 2016 Dec 28; 11(12):e0167348. PubMed ID: 27923051
    [Abstract] [Full Text] [Related]

  • 36.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 37.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 38.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 39.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 40. Availability of human induced pluripotent stem cell-derived cardiomyocytes in assessment of drug potential for QT prolongation.
    Nozaki Y, Honda Y, Tsujimoto S, Watanabe H, Kunimatsu T, Funabashi H.
    Toxicol Appl Pharmacol; 2014 Jul 01; 278(1):72-7. PubMed ID: 24742750
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 14.